Increased serum concentration of the soluble interleukin-2 receptor in cutaneous T-cell lymphoma: Clinical and prognostic implications

Archives of Dermatology

Volumn 132, Issue 1, 1996, Pages 42-47

  Wasik, Mariusz A ^a,d   Vonderheid, Eric C ^b   Bigler, Robert D ^b   Marti, Rosa ^a,c   Lessin, Stuart R ^d   Polansky, Marcia ^b   Kadin, Marshall E ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF LLEIDA   (Spain)

^d HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 2 RECEPTOR; LACTATE DEHYDROGENASE;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CELL COUNT; ERYTHRODERMA; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; LYMPHOMATOID PAPULOSIS; MAJOR CLINICAL STUDY; MALE; MYCOSIS FUNGOIDES; PRIORITY JOURNAL; PROGNOSIS; SEZARY CELL; SKIN BIOPSY; SURVIVAL RATE; T CELL LYMPHOMA;

ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; FEMALE; HUMANS; L-LACTATE DEHYDROGENASE; LYMPHOMA, T-CELL, CUTANEOUS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECEPTORS, INTERLEUKIN-2; SKIN; SOLUBILITY; SURVIVAL RATE;

EID: 0030021384     PISSN: 0003987X     EISSN: None     Source Type: Journal    
DOI: 10.1001/archderm.132.1.42     Document Type: Article

References (40)

1. Wood GS Benign and malignant cutaneous lymphoproliferative disorders including mycosis fungoides. In: Knowles DM, ed. Neoplastic Hematopathology Baltimore, Md: Williams & Wilkins; 1992:917-952.
2. Vonderheld EC, Kantor GR, Pequignot EC, et al. Analysis of clinical, histopathologic and immunopathologic parameters in erythrodermic variants of cutaneous T-cell lymphoma with implications for staging In: Lambert WC, Giannotti B, van Vloten W, eds Basic Mechanisms of Physiologic and Aberrant Lymphoproliferation in the Skin New York, NY Plenum Press, 1994:275-290.
3. Winkelmann RK, Buechner SA, Diaz-Perez JL Pre-Sézary syndrome. J Am Acad Dermatol 1984,10:992-999.
4. Vonderheid EC, Sobel EL, Nowell PC, Finan JB, Heltrich MK, Whipple DS. Diagnostic and prognostic significance of Sézary cells in peripheral blood smears from patients with cutaneous T-cell lymphoma. Blood. 1985;66:358-366.
5. Schechter GP, Sausville EA, Fischmann AB. et al. Evaluation of circulating malignant cells provides prognostic information in cutaneous T cell lymphoma. Blood. 1987;69 841-849.
6. Willemze R, van Vloten WA, Hermans J, Damsteeg MJM, Meijer CJLM. Diagnostic criteria in Sézary's syndrome a multiparameter study of the peripheral blood lymphocytes in 32 patients with erythroderma J Invest Dermatol. 1983; 81 392-398.
7. Wieselthier JS, Koh HK. Sézary syndrome: diagnosis, prognosis, and critical review of treatment options J Am Acad Dermatol 1990;22:381-401.
8. + large cell lymphomas of the skin: pathology, immunology, natural history and relevance to Hodgkin's disease. In. Hanaoka K, Kadin ME, Nanba K, Watanabe S, eds. International Colloquium on Lymphoid Malignancy: Immunocytology and Cytogenetics Philadelphia, Pa: Field & Woods, 1990 189-195.
9. Willemze R, Beljaards RC. Spectrum of primary cutaneous CD30 (Ki-1)-positive lymphoproliferative disorders a proposal for classification and guidelines for management and treatment. J Am Acad Dermatol 1993,28. 973-980
10. Karp DL, Horn TD. Lymphomatoid papulosis J Am Acad Dermatol. 1994.30: 379-395
11. Kadin M, Nasu K, Sako D, Said J, Vonderheid EC. Lymphomatoid papulosis: a cutaneous proliferation of activated helper T cells expressing Hodgkin's disease - associated antigens. Am J Pathol. 1985;119 315-325.
12. Wood GS, Strickler JG, Deneau DG, Egbert B, Warnke RA. Lymphomatoid papulosis expresses immunophenotypes associated with T cell lymphoma but not inflammation. J Am Acad Dermatol 1986,15:444-458.
13. Parks JD, Synovec MS, Masih AS, et al Immunophenotypic and genotypic characterization of lymphomatoid papulosis. J Am Acad Dermatol 1992;26: 968-975
14. Minami Y, Kono T, Miyazaki T, Taniguchi T. The IL-2 receptor complex its structure, function, and target genes. Annu Rev Immunol 1993;11:245-267.
15. Taniguchi T, Minami Y. The IL-2/IL-2 receptor system: a current overview. Cell. 1993,73 5-8
16. Rubin LA, Nelson DL The soluble interleukin-2 receptor: biology, function, and clinical application Ann Intern Med. 113:619-627.
17. Josimovic-Alasevic O, Herrman T, Diamantstein T. Demonstration of two distinct forms of released low-affinity type interleukin 2 receptors Eur J Immunol. 1988;18.1855-1857.
18. Fernandez-Botran, R Soluble cytokine receptors: their role in immunoregulation. FASEB J 1991;5:2567-2574
19. Kaudewitz P, Josimovic-Alasevic O, Diamantstein T, Eckert F, Klepzig K, Burg G Soluble IL-2 receptor serum levels in cutaneous T cell lymphoma correlation with clinical status and IL-2 receptor status in cutaneous infiltrates. J Invest Dermatol. 1988;91:386-387.
20. Zachariae C, Larsen CS, Kaltoft K, Deleuran B, Larsen CG, Thestrup-Pedersen K. Soluble IL2 receptor serum levels and epidermal cytokines in mycosis fungoides and related disorders. Acta Derm Venereol. 1991;71:465-470.
21. Dummer R, Nestle F, Wiede J, et al. Coincidence of increased soluble interleukin-2 receptors, diminished natural killer cell activity and progressive disease in cutaneous T-cell lymphomas. Eur J Dermatol. 1991;1:135-138.
22. Szeimies R-M, Rueff F, Kaudewitz P. Soluble interleukin-2 receptor serum levels in mycosis fungoides: correlation with clinical stage. Cancer. 1992;70: 2338-2341.
23. Bernengo MG, Fierro MT, Novelli M, Lisa F, Appino A. Soluble interleukin-2 receptor in Sézary syndrome: its origin and clinical application. Br J Dermatol 1993,128:124-129.
24. Goldman BD, Oh SK, Davis BE, Kadin ME, Poiesz BJ, Koh HK. Serum soluble interleukin 2 receptor levels in erythrodermic cutaneous T-cell lymphoma correlate with response to photopheresis-based treatment Arch Dermatol. 1993; 129 1166-1170.
25. Hamon MD, Unal E, MacDonald I, Shamim F, Boesen E, Prentice HG. Plasma soluble interleukin 2 receptor levels in patients with malignant lymphoma are correlated with disease activity but not cellular immunosuppression. Leuk Lymphoma. 1993;10:111-115.
26. Oishi M, Johno M, Ono T, Honda M Differences in IL-2 receptor levels between mycosis fungoides and cutaneous type adult T-cell leukemia/lymphoma in the early stages of the disease. J Invest Dermatol. 1994;102:710-715.
27. Bunn PA Jr, Lamberg SI. Report of the Committee on Staging and Classification of Cutaneous T-Cell Lymphomas. Cancer Treat Rep. 1979;63:725-728
28. Wasik M, Muirhead D, Rubocki R, Milgrom F Enzyme immunoassay with cell suspensions: studies on reactions between serum antibodies and cell-surface antigens. Int Arch Allergy Appl Immunol. 1986;81 269-275
29. Muramoto LM, Kadin ME. Improved detection of lymphoid cell surface antigens in tissues fixed in periodate-lysine-paraformaldehyde (PLP). Am J Clin Pathol 1987;88.589-595.
30. Said JW, Stoll PN, Shintaku P, Bindl JM, Butmarc JR, Pinkus GS. Leu-22 a preferential marker for T-lymphocytes in paraffin sections. Am J Clin Pathol. 1989.91 542-549
31. Rook AH, Prystrowsky MB, Cassin M, Boufal M, Lessin SR. Combined therapy for Sézary syndrome with extracorporeal photochemotherapy with low-dose interferon alfa therapy. Arch Dermatol. 1991,127.1535-1541
32. Pan L, Beverley PCL, Isaacson PG. Lactate dehydrogenase (LDH) isoenzymes and proliferative activity of lymphoid cells an immunocytochemical study. Clin Exp Immunol 1991,86 240-245
33. Shipp MA Prognostic factors in aggressive non-Hodgkin's lymphoma who has 'high-risk' disease? Blood. 1994;83.1165-1173
34. Wagner DK, Kiawanuka J, Edwards BK, Rubin LA, Nelson DL, Magrath IT Soluble interleukin-2 receptor levels in patients with undifferentiated and lymphoblastic lymphomas correlation with survival. J Clin Oncol 1987;5 1262-1274.
35. Pui CH, Ip SH, Kung P, et al. High serum interleukin-2 receptor levels are related to advanced disease and a poor outcome in childhood non-Hodgkin's lymphoma Blood. 1987,70:624-628
36. Wood NL, Kitces EW, Blaylock WK Depressed lymphokine-activated killer cell activity in mycosis fungoides. Arch Dermatol. 1990,126 907-913.
37. Dummer R, Posseckert G, Nestle F, et al Soluble interleukin-2 receptors inhibit interleukin 2-dependent proliferation and cytotoxicity explanation for diminished natural killer cell activity in cutaneous T-cell lymphomas in vivo? J Invest Dermatol 1992,98:50-54
38. Vonderheid EC, Tan E, Sobel EL, Schwab E, Micaily B, Jegasothy BV. Clinical implications of immunologic phenotyping in cutaneous T cell lymphoma. J Am Acad Dermatol 1987;17 40-52
39. Wasik MA, Sioutos N, Turtle M, Butmarc JR, Kadin ME. Constitutive secretion of soluble IL-2 receptor by human T-cell lymphoma xenografted into SCID mice: correlation of tumor volume with concentration of tumor-derived soluble interleukin-2 receptor in body fluids of the host mice Am J Pathol. 1994,144: 1089-1097
40. Dummer R, Burg G, Nestle F, Kohl O Soluble interleukin-2 receptors and cutaneous T-cell lymphoma Cancer 1993;71:3793-3794.